You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Details for Patent: 9,597,288

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,597,288 protect, and when does it expire?

Patent 9,597,288 protects ONSOLIS and is included in one NDA.

This patent has forty-four patent family members in twenty-four countries.

Summary for Patent: 9,597,288

Title:	Transmucosal delivery devices with enhanced uptake
Abstract:	The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.
Inventor(s):	Finn; Andrew (Raleigh, NC), Vasisht; Niraj (Cary, NC)
Assignee:	BioDelivery Sciences International, Inc. (Raleigh, NC)
Application Number:	15/198,961
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,597,288
Patent Claim Types: see list of patent claims	Use; Delivery; Device;

Drugs Protected by US Patent 9,597,288

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Adalvo	ONSOLIS	fentanyl citrate	FILM;BUCCAL	022266-001	Jul 16, 2009		DISCN	No	No	⤷ Sign Up	⤷ Sign Up	Y			MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER	⤷ Sign Up
Adalvo	ONSOLIS	fentanyl citrate	FILM;BUCCAL	022266-002	Jul 16, 2009		DISCN	No	No	⤷ Sign Up	⤷ Sign Up	Y			MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER	⤷ Sign Up
Adalvo	ONSOLIS	fentanyl citrate	FILM;BUCCAL	022266-003	Jul 16, 2009		DISCN	No	No	⤷ Sign Up	⤷ Sign Up	Y			MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER	⤷ Sign Up
Adalvo	ONSOLIS	fentanyl citrate	FILM;BUCCAL	022266-004	Jul 16, 2009		DISCN	No	No	⤷ Sign Up	⤷ Sign Up	Y			MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER	⤷ Sign Up
Adalvo	ONSOLIS	fentanyl citrate	FILM;BUCCAL	022266-005	Jul 16, 2009		DISCN	No	No	⤷ Sign Up	⤷ Sign Up	Y			MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,597,288

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007275581	⤷ Sign Up
Brazil	122020000250	⤷ Sign Up
Brazil	PI0714712	⤷ Sign Up
Canada	2658585	⤷ Sign Up
China	101511337	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.